Literature DB >> 28970096

Epidemiology and microbiological profile comparison between community and hospital acquired infections: A multicenter retrospective study in Lebanon.

Roula Matta1, Souheil Hallit2, Rabih Hallit3, Wafaa Bawab1, Anne-Marie Rogues4, Pascale Salameh5.   

Abstract

BACKGROUND: The objective of this study is to identify and characterize the species resistance of different pathogens between community acquired and hospital acquired infections pointing at patients' related independent co-morbidities and socio-demographic factors.
METHODS: It was a retrospective cohort, multicenter study from five private hospitals located in Beirut and Mount Lebanon. Two hundred fifty-eight adult patients were included.
RESULTS: 110 Gram negative pathogens and 26 Gram positive pathogens were implicated in hospital acquired infections. The Gram-negative bacteria that showed a positive correlation regarding patient's type of infection were Pseudomonas aeruginosa (12%), Klebsiella pneumoniae (6.2%) and Acinetobacter baumannii (3.1%). These bacteria were more frequent in patients with hospital acquired infections (P=0.002, 0.013 and 0.017 respectively). The ratio of methicillin resistant Staphylococcus aureus, Extended Spectrum Beta Lactamase producing Escherichia coli and K. pneumoniae and multi drug P. aeruginosa showed high significance in hospital acquired infections. The logistic regression, showed a significant relationship between resistant bacteria and age (p<0.001, ORa=5.680, CI [2.344; 13.765]) and immunosuppressed state (p=0.003, ORa=3.137, CI [1.485; 6.630]) and an inverse relationship for Chronic Obstructive Pulmonary Disease (COPD) (p=0.006, ORa=0.403, CI [0.212; 0.765]).
CONCLUSION: Our results confirm that hospital acquired infections/bacteria have higher rates of resistance when compared to community acquired; these rates increase with age, immunosuppression and are inversely proportional with COPD. Therefore, physicians should be aware of patients' comorbidities to properly guide initial therapy.
Copyright © 2017 The Authors. Published by Elsevier Ltd.. All rights reserved.

Entities:  

Keywords:  Acquired infections; Community; Hospital; Resistance

Mesh:

Substances:

Year:  2017        PMID: 28970096     DOI: 10.1016/j.jiph.2017.09.005

Source DB:  PubMed          Journal:  J Infect Public Health        ISSN: 1876-0341            Impact factor:   3.718


  16 in total

Review 1.  Antimicrobial Resistance Surveillance in Low- and Middle-Income Countries: Progress and Challenges in Eight South Asian and Southeast Asian Countries.

Authors:  Sumanth Gandra; Gerardo Alvarez-Uria; Paul Turner; Jyoti Joshi; Direk Limmathurotsakul; H Rogier van Doorn
Journal:  Clin Microbiol Rev       Date:  2020-06-10       Impact factor: 26.132

2.  Readmission Rates in Stroke Patients with and without Infections: Incidence and Risk Factors.

Authors:  Amelia K Boehme; Maitreyi Oka; Bevin Cohen; Mitchell S V Elkind; Elaine Larson; Barun Mathema
Journal:  J Stroke Cerebrovasc Dis       Date:  2021-11-16       Impact factor: 2.136

3.  Effects of Gentamicin-Loaded Chitosan-ZnO Nanocomposite on Quorum-Sensing Regulation of Pseudomonas Aeruginosa.

Authors:  Fatemeh Hemmati; Reza Ghotaslou; Roya Salehi; Hossein Samadi Kafil; Alka Hasani; Pourya Gholizadeh; Roghayeh Nouri; Mohammad Ahangarzadeh Rezaee
Journal:  Mol Biotechnol       Date:  2021-05-18       Impact factor: 2.695

Review 4.  Epidemiology of Multidrug-Resistant Pseudomonas aeruginosa in the Middle East and North Africa Region.

Authors:  Mahmood Al-Orphaly; Hamad Abdel Hadi; Faiha Kamaleldin Eltayeb; Hissa Al-Hail; Bincy Gladson Samuel; Ali A Sultan; Sini Skariah
Journal:  mSphere       Date:  2021-05-19       Impact factor: 4.389

5.  A compilation of antimicrobial susceptibility data from a network of 13 Lebanese hospitals reflecting the national situation during 2015-2016.

Authors:  Rima Moghnieh; Georges F Araj; Lyn Awad; Ziad Daoud; Jacques E Mokhbat; Tamima Jisr; Dania Abdallah; Nadim Azar; Noha Irani-Hakimeh; Maher M Balkis; Mona Youssef; Gilbert Karayakoupoglou; Monzer Hamze; Madonna Matar; Roula Atoui; Edmond Abboud; Rita Feghali; Nadine Yared; Rola Husni
Journal:  Antimicrob Resist Infect Control       Date:  2019-02-20       Impact factor: 4.887

6.  Comparative Study Of Genetic Diversity, Virulence Genotype, Biofilm Formation And Antimicrobial Resistance Of Uropathogenic Escherichia coli (UPEC) Isolated From Nosocomial And Community Acquired Urinary Tract Infections.

Authors:  Gabrielle Messias De Souza; Estevan Rodrigues Dos Santos Neto; Alaor Martins da Silva; Maria Vitoria Minzoni de Souza Iacia; Marcus Vinícius Pimenta Rodrigues; Valéria Cataneli Pereira; Lizziane Kretli Winkelstroter
Journal:  Infect Drug Resist       Date:  2019-11-22       Impact factor: 4.003

7.  The incidence and prevalence of hospital-acquired (carbapenem-resistant) Acinetobacter baumannii in Europe, Eastern Mediterranean and Africa: a systematic review and meta-analysis.

Authors:  Olaniyi Ayobami; Niklas Willrich; Thomas Harder; Iruka N Okeke; Tim Eckmanns; Robby Markwart
Journal:  Emerg Microbes Infect       Date:  2019       Impact factor: 7.163

8.  Twitching motility of Stenotrophomonas maltophilia under iron limitation: In-silico, phenotypic and proteomic approaches.

Authors:  Kalidasan V; Vasantha Kumari Neela
Journal:  Virulence       Date:  2020-12       Impact factor: 5.882

9.  The relationship between phylogenetic groups and antibiotic susceptibility patterns of Escherichia coli strains isolated from feces and urine of patients with acute or recurrent urinary tract infection.

Authors:  Hossein Norouzian; Mohammad Katouli; Nader Shahrokhi; Sharam Sabeti; Mohammad Pooya; Saeid Bouzari
Journal:  Iran J Microbiol       Date:  2019-12

10.  Significant association between genes encoding virulence factors with antibiotic resistance and phylogenetic groups in community acquired uropathogenic Escherichia coli isolates.

Authors:  Zahra Yazdanpour; Omid Tadjrobehkar; Motahareh Shahkhah
Journal:  BMC Microbiol       Date:  2020-08-05       Impact factor: 3.605

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.